A phase II study of CI-973 [SP4-3(R)]- [1, 1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N′) platinum in patients with refractory advanced breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 3, 1996, Pages 289-291

  Theriault, Richard L ^a   Walters, Ronald S ^a   Holmes, Frankie Ann ^a   Esparza Guerra, Laura ^a   Kowal, Charles ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; CI 973

Indexed keywords

PLATINUM COMPLEX; SEBRIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; HEMATOLOGY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOMAGNESEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER FUNCTION; METASTASIS; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; PLATELET COUNT; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS;

EID: 0029940217     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050484     Document Type: Article

References (13)

1. Fukuoka M, Niitani H, Hasegawa K, Majima H, Hino M, Furue H, Tsukagoshi S, Fujita H, Ohta K, Furuse K, Kimura S, Katoh T (1989) Phase I study of a new platinum compound, NK121. Proc Am Soc Clin Oncol 8:62
2. 1) patient. (NK121/CI-973. Proc Am Assoc Cancer Res 344:1370
3. 1] platinum in patients with metastatic solid tumors. Cancer Chemother Pharmacol 31: 333-337
4. O'Dwyer PJ, Hudes GR, Walozak J, Schilder R, La Creta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA (1992) Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule. Cancer Res 52: 6746-6753
5. Zubrod C, Schneiderman M, Frei E, et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: a comparative trial of nitrogen mustard and trimethylene thiophosphoromide. J Chron Dis 11: 7-33
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
7. WHO Handbook for Reporting Results of Cancer Treatment (1979) WHO offset publication no. 48. WHO, Geneva
8. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1294
9. Casper ES, Smart TC, Hakes TB, Ochoa M Jr, Kaufman RJ (1988) Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum TV, CHIP) in patients with advanced breast cancer. Invest New Drugs 6: 87-91
10. Hortobagyi GN, Frye D, holmes FA, Hug V, Fraschini G, Buzdar AU (1987) Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep 71: 1193-1196
11. Meisner DJ, Ginsberg S, Ditch A, Louie A, Newman N, Conis B, Poiez B (1989) A phase II trial of iproplatin (CHIP) in previously treated advanced breast cancer. Am J Clin Oncol 12: 129-131
12. Martin M, Diaz-Rubio E, Casado A, Santabarbara P, Lopez Vega JM, Adrores E, Lenaz L (1992) Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 10: 433-437
13. Kolaric K, Vukas D (1991) Carboplatin activity in untreated metastatic breast cancer patients - results of a phase II study. Cancer Chemother Pharmacol 27: 409-412